Shenzhen Weiguang Biological Products Co Ltd
Shenzhen Weiguang Biological Products Co., Ltd. primarily engages in the research, development, production, and sale of blood products in China. The company offers human factor VIII, human immunoglobulin (PH4), human rabies immunoglobulin, human tetanus immunoglobulin, human hepatitis B immunoglobulin, human albumin, human histaglobulin, human firbrinogen, human immunoglobulin for intravenous inj… Read more
Shenzhen Weiguang Biological Products Co Ltd - Asset Resilience Ratio
Shenzhen Weiguang Biological Products Co Ltd (002880) has an Asset Resilience Ratio of 5.52% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Shenzhen Weiguang Biological Products Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Shenzhen Weiguang Biological Products Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥169.93 Million | 5.52% |
| Total Liquid Assets | CN¥169.93 Million | 5.52% |
Asset Resilience Insights
- Limited Liquidity: Shenzhen Weiguang Biological Products Co Ltd maintains only 5.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shenzhen Weiguang Biological Products Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shenzhen Weiguang Biological Products Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Shenzhen Weiguang Biological Products Co Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Shenzhen Weiguang Biological Products Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.65% | CN¥153.32 Million | CN¥3.30 Billion | +27.52pp |
| 2023-12-31 | -22.87% | CN¥-658.04 Million | CN¥2.88 Billion | -15.75pp |
| 2022-12-31 | -7.12% | CN¥-183.51 Million | CN¥2.58 Billion | -5.95pp |
| 2021-12-31 | -1.17% | CN¥-23.53 Million | CN¥2.00 Billion | -0.94pp |
| 2020-12-31 | -0.23% | CN¥-4.25 Million | CN¥1.84 Billion | -- |